Korean J Med.  2010 Apr;78(4):425-429.

Management of systemic lupus erythematosus

Affiliations
  • 1Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.

Abstract

Systemic lupus erythematosus (SLE) is an autoimmune disorder which affects the musculoskelectal system, skin, kidney, central nervous system, gastrointestinal tract, and vascular system. The therapeutic level depends on the severity of SLE activity and affected organ damage. The prognosis of SLE has greatly improved since treatment regimens combining corticosteroids and immunosuppressive agents have been widely adopted in therapeutic strategies. Immune suppression is evidently effective, however, sometimes leads to higher susceptibility to infectious and malignant diseases. Toxic effects and unexpectedly fatal complications of current therapies have been progressively reported. Currently, identifying novel molecular targets such as hyperactive B cells could be an important issue in the treatment of SLE. The aim of this review is the introduction of previous adopted therapies as well as emerging pharmacological options.

Keyword

Systemic lupus erythematosus; Treatment; Immunosuppressive agent

MeSH Terms

Adrenal Cortex Hormones
B-Lymphocytes
Central Nervous System
Gastrointestinal Tract
Immunosuppressive Agents
Kidney
Lupus Erythematosus, Systemic
Prognosis
Skin
Adrenal Cortex Hormones
Immunosuppressive Agents
Full Text Links
  • KJM
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr